Pages that link to "Q56558418"

The following pages link to Thomas Karagiannis (Q56558418):

Displaying 28 items.

• Safety of dipeptidyl peptidase 4 inhibitors: a perspective review (Q26863262) (← links)
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis (Q34031108) (← links)
• Gestational diabetes mellitus: why screen and how to diagnose. (Q34144969) (← links)
• Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis (Q34985373) (← links)
• Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis (Q35157497) (← links)
• Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus (Q35528766) (← links)
• Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials (Q35784245) (← links)
• Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial (Q37454939) (← links)
• Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy (Q37712199) (← links)
• A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis (Q38177019) (← links)
• Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. (Q38682317) (← links)
• Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications (Q38901098) (← links)
• Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis (Q38971754) (← links)
• Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. (Q39266678) (← links)
• Most add-on therapies to metformin have similar effects on HbA1c. (Q51453969) (← links)
• Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. (Q53280517) (← links)
• Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis (Q57174256) (← links)
• Premixed insulin regimens for type 2 diabetes (Q86877387) (← links)
• In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER (Q88421961) (← links)
• Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis (Q88658235) (← links)
• Meta-analysis of artificial pancreas trials: methodological considerations (Q88851066) (← links)
• Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis (Q90866848) (← links)
• Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis (Q91804906) (← links)
• Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study (Q92389588) (← links)
• Gestational diabetes mellitus: why screen and how to diagnose (Q93540535) (← links)
• Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis (Q96020204) (← links)
• Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis (Q96770244) (← links)
• Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis (Q104259036) (← links)